Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02049333
Other study ID # ECPLateau10.1
Secondary ID
Status Completed
Phase N/A
First received January 27, 2014
Last updated January 29, 2014
Start date November 2010
Est. completion date November 2013

Study information

Verified date January 2014
Source Credit Valley EyeCare
Contact n/a
Is FDA regulated No
Health authority Canada: Canadian Food & Drug Act & Regulations
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess and compare the mechanical angle opening in patients with angle closure due to a plateau iris configuration (elevated iris) using phacoemulsification combined with endoscopic cycloplasty versus treatment with phacoemulsification alone.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient has to be = 18 years of age of either gender

- Nuclear sclerotic cataract graded by LOCS III to be < 5

- Diagnosis of Plateau Iris Configuration or Syndrome

- No contraindication for cataract or ECPL operation

- Written informed consent on IRB approved Informed Consent Form

Exclusion Criteria:

- Hard cataracts, LOCS III 5 and 6

- Ciliary body cysts

- Clinically significant sequelae from trauma in which angle anatomy/physiology may have been compromised (e.g., chemical burns, significant angle recession, blunt trauma, etc.)

- Congenital anomaly of the irido-trabecular angle

- Previous intraocular surgery

- Previous laser gonioplasty to either eye

- Placement of the intraocular lens in any place other than the capsular bag

- Pupilloplasty

- Rubeosis

- Peripheral anterior synechiae (PAS) nasal angle and/or >180 degrees of PAS

- Neovascular glaucoma; or glaucoma associated with vascular ischemic disorders

- Active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis)

- Corneal opacities or disorders that would inhibit visualization of the nasal angle

- Chronic ocular inflammatory disease or presence of active ocular inflammation with risk for synechial/proliferative changes

- Inability to attend regular follow-up assessment or to give informed written consent.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Phacoemulsification

Endoscopic Cycloplasty (ECPL)


Locations

Country Name City State
Canada Osler EyeCare Brampton Ontario
Canada Credit Valley EyeCare Mississauga Ontario

Sponsors (1)

Lead Sponsor Collaborator
Credit Valley EyeCare

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Intra- and post-operative complications Analyzing any unexpected complications from the surgery such as prolonged hypotony, intraocular pressure spike, prolonged corneal inflammation etc. This will be done during the clinic visit and analyzed under slit lamp examination. Up to one year after surgery Yes
Primary Anterior Chamber Angle Depth (nasal angle) Anterior chamber angle depth (nasal angle) measured using the Shaffer grading system and via anterior segment imaging Twelve months No
Secondary Number of glaucoma medications The number of glaucoma medications will be recorded and compared to pre-operative number of glaucoma medications. Twelve months post-op No
Secondary Intraocular pressure (IOP) IOP will be recorded and compared to pre-operative IOP. Twelve months post-op No
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A